William L. Seibel, PhD

Member, Division of Oncology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-803-4870

Fax 513-636-3549

Email william.seibel@cchmc.org

Small molecule drug discovery
William Seibel, PhD, completed his doctorate in chemistry at Harvard University. He then worked for 19 years in various positions at Procter & Gamble Pharmaceuticals, managing migraine and antimicrobials drug discovery groups as well as technology groups in computational, modeling, structural biology and combinatorial chemistry. He then served as head of the University of Cincinnati College of Medicine’s Compound Library and Cheminformatics group and as project manager for the Drug Discovery Center, both of which continue through his Cincinnati Children's Hospital Medical Center appointment. His interests are in working with various collaborators to find the most efficient and effective approaches to identify biologically active small molecules, and advance these leads to clinical candidate status.
PhD: Harvard University, Cambridge, MA, 1987.

View PubMed Publications

Fells JI, Lee SC, Fujiwara Y, Norman DD, Lim KG, Tsukahara R, Liu J, Patil R, Miller DD, Kirby RJ, Nelson S, Seibel W, Papoian R, Parrill AL, Baker DL, Bittman R, Tigyi G.  Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surfaceMol Pharmacol. 2013 Sep;84(3):415-24.

Cash JN, Angerman EB, Kirby RJ, Merck L, Seibel WL, Wortman MD, Papoian R, Nelson S, Thompson TB.  Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin AJ Biomol Screen. 2013 Aug;18(7):837-44.

Panmanee W, Taylor D, Shea CJ, Tang H, Nelson S, Seibel W, Papoian R, Kramer R, Hassett DJ, Lamkin TJ.  High-throughput screening for small-molecule inhibitors of Staphylococcus epidermidis RP62a biofilms.  J Biomol Screen. 2013 Aug;18(7):820-9.

Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, Wortman M, Zheng Y. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60.

Shang X, Marchioni F, Sipes N, Evelyn CR, Jerabek-Willemsen M, Duhr S, Seibel W, Wortman M, Zheng Y.  Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol. 2012 Jun 22;19(6):699-710.

Tan Z, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, Smith SJ, Malkas LH, Zheng Y, Lu S, Dong Z. Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growthMol Pharmacol. 2012 Jun;81(6):811-9.

Bosco EE, Kumar S, Marchioni F, Biesiada J, Kordos M, Szczur K, Meller J, Seibel W, Mizrahi A, Pick E, Filippi MD, Zheng Y.  Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammationChem Biol. 2012 Feb 24;19(2):228-42.

Barger JF, Gallo CA, Torni KA, Merk L, Seibel WL, Nelson S, Plas DR. Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responses to rapamycin. Cancer Biol Ther. 2010 Dec 15;10(12):1256-61.

Rathore R, Pribil P, Corr JJ, Seibel WL, Evdokimov A, Greis KD. Multiplex enzyme assays and inhibitor screening by mass spectrometry.  J Biomol Screen.  2010 Sep;15(8):1001-7.

Rathore R, Corr JJ, Lebre DT, Seibel WL, Greis KD. Extending matrix-assisted laser desorption/ionization triple quadrupole mass spectrometry enzyme screening assays to targets with small molecule substrates. Rapid Commun Mass Spectrom.  2009 Oct 30;23(20):3293-300.